ITMI20072162A1 - COLLIRIO FOR THE TREATMENT OF KERATOCONO WITH TRANS-EPITHELIAL CROSS-LINKING TECHNIQUE - Google Patents
COLLIRIO FOR THE TREATMENT OF KERATOCONO WITH TRANS-EPITHELIAL CROSS-LINKING TECHNIQUE Download PDFInfo
- Publication number
- ITMI20072162A1 ITMI20072162A1 ITMI20072162A ITMI20072162A1 IT MI20072162 A1 ITMI20072162 A1 IT MI20072162A1 IT MI20072162 A ITMI20072162 A IT MI20072162A IT MI20072162 A1 ITMI20072162 A1 IT MI20072162A1
- Authority
- IT
- Italy
- Prior art keywords
- eye drops
- treatment
- riboflavin
- keratoconus
- trans
- Prior art date
Links
- 238000004132 cross linking Methods 0.000 title claims description 6
- 238000000034 method Methods 0.000 title claims description 5
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 21
- 239000003889 eye drop Substances 0.000 claims description 21
- 229940012356 eye drops Drugs 0.000 claims description 20
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 11
- 229960002477 riboflavin Drugs 0.000 claims description 11
- 235000019192 riboflavin Nutrition 0.000 claims description 10
- 239000002151 riboflavin Substances 0.000 claims description 10
- 201000002287 Keratoconus Diseases 0.000 claims description 9
- 210000003560 epithelium corneal Anatomy 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 4
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 230000035515 penetration Effects 0.000 claims description 3
- 230000002165 photosensitisation Effects 0.000 claims description 3
- 239000004231 Riboflavin-5-Sodium Phosphate Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 235000019234 riboflavin-5-sodium phosphate Nutrition 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000008223 sterile water Substances 0.000 claims description 2
- 208000017983 photosensitivity disease Diseases 0.000 claims 2
- 231100000434 photosensitization Toxicity 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000003504 photosensitizing agent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 206010011033 Corneal oedema Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 201000004778 corneal edema Diseases 0.000 description 1
- 231100000269 corneal opacity Toxicity 0.000 description 1
- 210000003683 corneal stroma Anatomy 0.000 description 1
- 230000004453 corneal transparency Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Description
Descrizione dell’invenzione industriale avente per titolo: Description of the industrial invention entitled:
“Collirio per il trattamento del cheratocono con tecnica «cross-linking» trans-epiteliale”. "Eye drops for the treatment of keratoconus with trans-epithelial" cross-linking "technique".
Riassunto del trovato Summary of the finding
Collirio per il trattamento dei pazienti affetti da cheratocono contenente la sostanza fotosensibilizzante riboflavina ed un composto tensioattivo per favorire la penetrazione del collirio nell’epitelio corneale; rispetto ai normali colliri per il trattamento del cheratocono, il prodotto secondo l’invenzione ha il vantaggio di non richiedere la rimozione dell’epitelio corneale, con assenza di dolore per il paziente, il quale non necessita di particolari terapie post trattamento, non accusa più alcun edema dovuto alla rimozione dell’epitelio e conserva la originaria trasparenza corneale. Eye drops for the treatment of patients suffering from keratoconus containing the photosensitizing substance riboflavin and a surfactant compound to facilitate the penetration of the eye drops into the corneal epithelium; Compared to normal eye drops for the treatment of keratoconus, the product according to the invention has the advantage of not requiring the removal of the corneal epithelium, with the absence of pain for the patient, who does not require particular post-treatment therapies, no longer accuses no edema due to the removal of the epithelium and retains the original corneal transparency.
Descrizione del trovato Description of the finding
La presente invenzione concerne un collirio migliorato per il trattamento con tecnica «cross-linking» trans-epiteliale dei pazienti affetti da cheratocono. The present invention relates to an improved eye drops for the trans-epithelial "cross-linking" treatment of patients affected by keratoconus.
Nelle persone affette da cheratocono, la cornea risulta più debole e risultano molto meno numerosi del normale i legami tra le fibre di collagene. In people with keratoconus, the cornea is weaker and the bonds between collagen fibers are much less numerous than normal.
Il cheratocono è una patologia progressiva e nella quasi totalità dei casi bilaterale, cioè colpisce entrambi gli occhi del paziente. Keratoconus is a progressive disease and in almost all cases bilateral, that is, it affects both eyes of the patient.
Allo scopo di irrigidire la struttura corneale e di favorire un aumento dei legami tra le fibre dì collagene corneale (cross-linking) è in uso instìllare ribof lavina in forma di collirio sulla cornea e fotosensibi lizzarla con una fonte di raggi UVA. I colliri attualmente noti a tale scopo necessitano, perché il trattamento risulti efficace, che l'epitelio corneale venga rimosso, con conseguenti episodi di edema corneale (opacità della cornea) post-trattamento e una lunga rìepìtelizzazione della parte trattata. In order to stiffen the corneal structure and promote an increase in the links between the corneal collagen fibers (cross-linking), it is in use to instill ribof lavin in the form of eye drops on the cornea and photosensitize it with a source of UVA rays. The eye drops currently known for this purpose require, for the treatment to be effective, that the corneal epithelium is removed, with consequent post-treatment episodes of corneal edema (corneal opacity) and a long epithelization of the treated part.
E’ scopo delia presente invenzione di fornire un nuovo collirio per il trattamento di tali pazienti che, a differenza di quelli esistenti, non richieda la rimozione dell'epitelio corneale. It is the purpose of the present invention to provide a new eye drops for the treatment of such patients which, unlike the existing ones, do not require the removal of the corneal epithelium.
Questo scopo è conseguito con un collirio contenente la sostanza fotosensi bilizzante riboflavina ed un composto tensio-attivo che favorisce la penetrazione del collirio nell’epitelio corneale. This purpose is achieved with an eye drop containing the photosensitive substance riboflavin and a surfactant compound that promotes the penetration of the eye drops into the corneal epithelium.
Preferiti modi di realizzare l’invenzione risultano dalle sottorivendicazioni. Preferred ways of carrying out the invention result from the sub-claims.
Altri scopi, vantaggi e caratteristiche risultano dal collirio realizzato secondo l’invenzione, qui descritto con riferimento ad alcuni esempi dì preparazione dello stesso. Other purposes, advantages and characteristics result from the eye drops made according to the invention, described here with reference to some examples of preparation of the same.
La procedura di somministrazione del collirio, concepito secondo la presente invenzione, risulta dal disegno allegato. Il collirio della presente invenzione contiene ribof lavina, ovvero la vitamina B2, presente in natura in alimenti come la frutta e le verdure. The procedure for administering the eye drops, conceived according to the present invention, results from the attached drawing. The eye drops of the present invention contain ribof lavin, or vitamin B2, naturally present in foods such as fruit and vegetables.
La riboflavina possiede capacità fotosensibilizzanti per cui, in presenza di raggi ultravioletti, accumula energia e la cede ai mezzi circostanti. Riboflavin possesses photosensitizing capabilities so that, in the presence of ultraviolet rays, it accumulates energy and transfers it to surrounding media.
Pertanto, quando viene instillata sulla cornea {stroma corneale), la quale è costituita essenzialmente da acqua e fibre di collagene, e viene poi colpita da una fonte di raggi UVA (sorgente da 3 mW/cm<2>e raggi di lunghezza d’onda pari a 370 nm), la riboflavina prima accumula energia e poi la cede alle molecole d’acqua provocandone l'idrolisi; gli ioni derivanti da questo processo (radicali liberi) sì legano alle fibre di collagene e ne rafforzano la struttura (cross-linking). Therefore, when it is instilled on the cornea {corneal stroma), which is essentially made up of water and collagen fibers, it is then hit by a source of UVA rays (source of 3 mW / cm <2> and rays of length of wave equal to 370 nm), the riboflavin first accumulates energy and then transfers it to the water molecules causing their hydrolysis; the ions deriving from this process (free radicals) bind to the collagen fibers and strengthen their structure (cross-linking).
La tradizionale necessità di rimuovere l'epitelio corneale è superata dalla presenza nel collirio oggetto dell’invenzione di un composto tensioattivo che ha il compito di far penetrare la riboflavina attraverso l'epitelio. The traditional need to remove the corneal epithelium is overcome by the presence in the eye drops object of the invention of a surfactant compound which has the task of making riboflavin penetrate through the epithelium.
Il tensioattivo preferito per l'invenzione è in particolare il Cloruro di Benzalconio. The preferred surfactant for the invention is in particular Benzalkonium Chloride.
Di seguito viene indicato un esempio di formulazione del collirio preparato secondo la presente invenzione; le quantità sono specificate per 100 mi di soluzione: An example of formulation of the eye drops prepared according to the present invention is indicated below; the quantities are specified per 100 ml of solution:
150 mg riboflavina-5-sodio fosfato (polvere) 150 mg riboflavin-5-sodium phosphate (powder)
440 mg Cloruro di Sodio (polvere) 440 mg Sodium Chloride (powder)
900 mg Acqua sterile (liquido) 900 mg Sterile water (liquid)
20 mg Cloruro di Benzalconio 20 mg Benzalkonium chloride
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20072162 ITMI20072162A1 (en) | 2007-11-14 | 2007-11-14 | COLLIRIO FOR THE TREATMENT OF KERATOCONO WITH TRANS-EPITHELIAL CROSS-LINKING TECHNIQUE |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20072162 ITMI20072162A1 (en) | 2007-11-14 | 2007-11-14 | COLLIRIO FOR THE TREATMENT OF KERATOCONO WITH TRANS-EPITHELIAL CROSS-LINKING TECHNIQUE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ITMI20072162A1 true ITMI20072162A1 (en) | 2009-05-15 |
Family
ID=40314707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ITMI20072162 ITMI20072162A1 (en) | 2007-11-14 | 2007-11-14 | COLLIRIO FOR THE TREATMENT OF KERATOCONO WITH TRANS-EPITHELIAL CROSS-LINKING TECHNIQUE |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | ITMI20072162A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2590638A1 (en) * | 2010-07-05 | 2013-05-15 | Roberto Pinelli | Trans-epithelial osmotic collyrium for the treatment of keratoconus |
-
2007
- 2007-11-14 IT ITMI20072162 patent/ITMI20072162A1/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2590638A1 (en) * | 2010-07-05 | 2013-05-15 | Roberto Pinelli | Trans-epithelial osmotic collyrium for the treatment of keratoconus |
| US20130267528A1 (en) * | 2010-07-05 | 2013-10-10 | Avedro, Inc. | Trans-epithelial osmotic collyrium for the treatment of keratoconus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2253321A1 (en) | Collyrium for the treatment of conial cornea with "cross-linking" trans-epithelial technique | |
| EP2323642B1 (en) | Use of EDTA+tromethamine or of photoenhancers, associated to riboflavin for corneal cross-linking in the treatment of the keratoconus or of other corneal ectasic disorders | |
| Xue et al. | Genipin-crosslinked donor sclera for posterior scleral contraction/reinforcement to fight progressive myopia | |
| Kugelberg et al. | Two‐year follow‐up of posterior capsule opacification after implantation of a hydrophilic or hydrophobic acrylic intraocular lens | |
| ITMI20101236A1 (en) | TRANS-EPITHELIAL OSMOTIC COLLIRIUM FOR THE CARE OF THE KERATOCONO. | |
| WO2008011836A3 (en) | Ophthalmic solutions | |
| WO2009143054A3 (en) | Intraocular lens with photosensitizer and method for modifying the refractive index of the lens | |
| RU2012101782A (en) | WATER PHARMACEUTICAL COMPOSITIONS CONTAINING BORATPOLIOL COMPLEXES | |
| CR7330A (en) | PROCEDURE FOR TREATING EYE NEOVASCULAR DISEASES | |
| JP2016507529A (en) | Artificial tears containing sodium hyaluronate and carboxymethylcellulose | |
| MY150250A (en) | Ketorolac tromethamine compositions for treating or preventing ocular pain | |
| Labetoulle et al. | Safety and efficacy of a hydroxypropyl guar/polyethylene glycol/propylene glycol-based lubricant eye-drop in patients with dry eye | |
| CN104375285A (en) | Blue-light-proof lens | |
| JP5913606B2 (en) | Improved cross-linking composition effective for the treatment of keratoconus and introduced by iontophoresis | |
| KR20120061841A (en) | Pharmaceutical composition for suppressing pain | |
| ITMI20072162A1 (en) | COLLIRIO FOR THE TREATMENT OF KERATOCONO WITH TRANS-EPITHELIAL CROSS-LINKING TECHNIQUE | |
| AR034372A1 (en) | PHARMACEUTICAL COMPOSITIONS | |
| US20060079482A1 (en) | Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same | |
| Vega-Estrada et al. | Biocompatibility and biomechanical effect of single wall carbon nanotubes implanted in the corneal stroma: a proof of concept investigation | |
| JP2019147755A (en) | Ophthalmic composition | |
| Bradford et al. | In vivo femtosecond laser machined transepithelial nonlinear optical corneal crosslinking compared to ultraviolet corneal crosslinking | |
| Ucakhan et al. | Outcome of two corneal collagen crosslinking methods in bullous keratopathy due to Fuchs’ endothelial dystrophy | |
| CN105853488A (en) | Novel eyedrops | |
| BRPI0512727A (en) | use of hyaluronic acid to increase lens regeneration | |
| MX2020012116A (en) | A synergic ophthalmological composition in low concentration dose effective in the prevention, control, and eradication of presbycia. |